Is CRIS or SNTI more profitable?

Senti Biosciences' return on equity of -1,629.80% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis N/A -2,365.94% -200.88% Senti Biosciences N/A -1,629.80% -119.72%

Does the media refer more to CRIS or SNTI?

In the previous week, Curis had 13 more articles in the media than Senti Biosciences. MarketBeat recorded 14 mentions for Curis and 1 mentions for Senti Biosciences. Curis' average media sentiment score of 0.13 beat Senti Biosciences' score of 0.00 indicating that Curis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SNGX or CRIS?

Curis has a consensus price target of $43.00, suggesting a potential upside of 4,643.52%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, SNGX or CRIS?

Curis has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soligenix $120K 41.37 -$11.08M -$0.98 N/A Curis $9.44M 0.39 -$7.58M -$14.22 N/A

Is SNGX or CRIS more profitable?

Soligenix's return on equity of -175.59% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -175.59% -98.99% Curis N/A -2,365.94% -200.88%

Does the media refer more to SNGX or CRIS?

In the previous week, Curis had 12 more articles in the media than Soligenix. MarketBeat recorded 14 mentions for Curis and 2 mentions for Soligenix. Soligenix's average media sentiment score of 1.50 beat Curis' score of 0.13 indicating that Soligenix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Curis 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, IMNN or CRIS?

Curis has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Imunon N/A N/A -$14.49M -$3.83 N/A Curis $9.44M 0.39 -$7.58M -$14.22 N/A

Is IMNN or CRIS more profitable?

Imunon's return on equity of -358.01% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -358.01% -132.91% Curis N/A -2,365.94% -200.88%

Does the media favor IMNN or CRIS?

In the previous week, Curis had 12 more articles in the media than Imunon. MarketBeat recorded 14 mentions for Curis and 2 mentions for Imunon. Curis' average media sentiment score of 0.13 beat Imunon's score of 0.00 indicating that Curis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Curis 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CRIS or CDIO?

Curis presently has a consensus target price of $43.00, suggesting a potential upside of 4,643.52%. Given Curis' stronger consensus rating and higher possible upside, equities analysts plainly believe Curis is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CRIS or CDIO more profitable?

Curis has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -83.52% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis N/A -2,365.94% -200.88% Cardio Diagnostics -40,543.75% -83.52% -77.07%

Do analysts recommend XBIO or CRIS?

Curis has a consensus target price of $43.00, indicating a potential upside of 4,643.52%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XBIO or CRIS more profitable?

Curis has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Xenetic Biosciences -75.90% -40.62% -34.97% Curis N/A -2,365.94% -200.88%

Does the media prefer XBIO or CRIS?

In the previous week, Curis had 13 more articles in the media than Xenetic Biosciences. MarketBeat recorded 14 mentions for Curis and 1 mentions for Xenetic Biosciences. Curis' average media sentiment score of 0.13 beat Xenetic Biosciences' score of 0.00 indicating that Curis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenetic Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Curis 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Curis (CRIS) Competitors

$0.91 0.00 (0.00%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$0.79 -0.12 (-12.74%)

As of 11/6/2026 07:58 PM Eastern

Compare

CRIS vs. SNTI, SNGX, IMNN, CDIO, and XBIO

Should you buy Curis stock or one of its competitors? Curis's main competitors and comparable companies include Senti Biosciences (SNTI), Soligenix (SNGX), Imunon (IMNN), Cardio Diagnostics (CDIO), and Xenetic Biosciences (XBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Curis compare to Senti Biosciences?

Curis (NASDAQ:CRIS) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Curis has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

30.0% of Curis shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 1.5% of Curis shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Curis has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.39	-$7.58M	-$14.22	N/A
Senti Biosciences	$20K	249.20	-$61.44M	-$1.77	N/A

Senti Biosciences' return on equity of -1,629.80% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	N/A	-2,365.94%	-200.88%
Senti Biosciences	N/A	-1,629.80%	-119.72%

Curis currently has a consensus price target of $43.00, suggesting a potential upside of 4,643.52%. Senti Biosciences has a consensus price target of $9.00, suggesting a potential upside of 5,525.00%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Curis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Curis had 13 more articles in the media than Senti Biosciences. MarketBeat recorded 14 mentions for Curis and 1 mentions for Senti Biosciences. Curis' average media sentiment score of 0.13 beat Senti Biosciences' score of 0.00 indicating that Curis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Senti Biosciences beats Curis on 8 of the 15 factors compared between the two stocks.

How does Curis compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

3.6% of Soligenix shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 1.9% of Soligenix shares are held by company insiders. Comparatively, 1.5% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Curis has a consensus price target of $43.00, suggesting a potential upside of 4,643.52%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Curis has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	41.37	-$11.08M	-$0.98	N/A
Curis	$9.44M	0.39	-$7.58M	-$14.22	N/A

Soligenix's return on equity of -175.59% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-175.59%	-98.99%
Curis	N/A	-2,365.94%	-200.88%

In the previous week, Curis had 12 more articles in the media than Soligenix. MarketBeat recorded 14 mentions for Curis and 2 mentions for Soligenix. Soligenix's average media sentiment score of 1.50 beat Curis' score of 0.13 indicating that Soligenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Curis	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soligenix has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Curis has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market.

Summary

Curis beats Soligenix on 9 of the 15 factors compared between the two stocks.

How does Curis compare to Imunon?

Imunon (NASDAQ:IMNN) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Imunon's return on equity of -358.01% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-358.01%	-132.91%
Curis	N/A	-2,365.94%	-200.88%

In the previous week, Curis had 12 more articles in the media than Imunon. MarketBeat recorded 14 mentions for Curis and 2 mentions for Imunon. Curis' average media sentiment score of 0.13 beat Imunon's score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curis	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon presently has a consensus target price of $10.00, indicating a potential upside of 1,083.71%. Curis has a consensus target price of $43.00, indicating a potential upside of 4,643.52%. Given Curis' higher probable upside, analysts plainly believe Curis is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.5% of Imunon shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 2.8% of Imunon shares are owned by company insiders. Comparatively, 1.5% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Curis has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$3.83	N/A
Curis	$9.44M	0.39	-$7.58M	-$14.22	N/A

Imunon has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, Curis has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

Summary

Curis beats Imunon on 8 of the 12 factors compared between the two stocks.

How does Curis compare to Cardio Diagnostics?

Curis (NASDAQ:CRIS) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Cardio Diagnostics has lower revenue, but higher earnings than Curis. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.39	-$7.58M	-$14.22	N/A
Cardio Diagnostics	$10K	495.80	-$6.50M	-$2.92	N/A

30.0% of Curis shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.5% of Curis shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Curis has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,543.75%. Cardio Diagnostics' return on equity of -83.52% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	N/A	-2,365.94%	-200.88%
Cardio Diagnostics	-40,543.75%	-83.52%	-77.07%

Curis has a beta of 3.28, indicating that its share price is 228% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

In the previous week, Curis had 13 more articles in the media than Cardio Diagnostics. MarketBeat recorded 14 mentions for Curis and 1 mentions for Cardio Diagnostics. Curis' average media sentiment score of 0.13 beat Cardio Diagnostics' score of -0.47 indicating that Curis is being referred to more favorably in the media.

Company	Overall Sentiment
Curis	Neutral
Cardio Diagnostics	Neutral

Curis presently has a consensus target price of $43.00, suggesting a potential upside of 4,643.52%. Given Curis' stronger consensus rating and higher possible upside, equities analysts plainly believe Curis is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Curis beats Cardio Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Curis compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Xenetic Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, Curis has a beta of 3.28, indicating that its stock price is 228% more volatile than the broader market.

Xenetic Biosciences has higher earnings, but lower revenue than Curis. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	1.39	-$2.68M	-$1.16	N/A
Curis	$9.44M	0.39	-$7.58M	-$14.22	N/A

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 1.5% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Curis has a consensus target price of $43.00, indicating a potential upside of 4,643.52%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Curis has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
Curis	N/A	-2,365.94%	-200.88%

In the previous week, Curis had 13 more articles in the media than Xenetic Biosciences. MarketBeat recorded 14 mentions for Curis and 1 mentions for Xenetic Biosciences. Curis' average media sentiment score of 0.13 beat Xenetic Biosciences' score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenetic Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curis	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Curis beats Xenetic Biosciences on 10 of the 16 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRIS vs. The Competition

Export

Metric	Curis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.72M	$4.14B	$7.79B	$11.80B
Dividend Yield	N/A	3.64%	2.47%	4.57%
P/E Ratio	-0.06	23.25	34.54	30.46
Price / Sales	0.39	16.81	8.79	5.73
Price / Cash	N/A	25.68	21.62	22.24
Price / Book	0.11	4.58	4.82	3.98
Net Income	-$7.58M	-$22.17M	$3.51B	$391.10M
7 Day Performance	37.14%	0.28%	-0.16%	-1.72%
1 Month Performance	35.06%	-8.03%	-5.26%	-7.75%
1 Year Performance	-96.54%	4.21%	2.65%	-6.76%

Curis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRIS Curis	2.0759 of 5 stars	$0.91 flat	$43.00 +4,643.5%	-96.5%	$3.72M	$9.44M	N/A	24	Upcoming Earnings Gap Down
SNTI Senti Biosciences	2.9171 of 5 stars	$0.17 -8.0%	$9.00 +5,102.3%	-91.8%	$5.39M	$55K	N/A	39	Upcoming Earnings Gap Down
SNGX Soligenix	1.0951 of 5 stars	$0.36 -0.3%	N/A	-75.5%	$5.34M	N/A	N/A	14	Earnings Report
IMNN Imunon	2.935 of 5 stars	$0.91 +4.8%	$10.00 +996.5%	-78.9%	$5.12M	N/A	N/A	20	Upcoming Earnings
CDIO Cardio Diagnostics	0.3981 of 5 stars	$1.61 -3.5%	N/A	-56.6%	$4.77M	$14.45K	N/A	17	Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRIS) was last updated on 11/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curis (CRIS) Competitors

CRIS vs. SNTI, SNGX, IMNN, CDIO, and XBIO

How does Curis compare to Senti Biosciences?

Summary

How does Curis compare to Soligenix?

Summary

How does Curis compare to Imunon?

Summary

How does Curis compare to Cardio Diagnostics?

Summary

How does Curis compare to Xenetic Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curis (CRIS) Competitors

CRIS vs. SNTI, SNGX, IMNN, CDIO, and XBIO

How does Curis compare to Senti Biosciences?

Which has more volatility & risk, CRIS or SNTI?

Do insiders and institutionals hold more shares of CRIS or SNTI?

Which has higher earnings & valuation, CRIS or SNTI?

Is CRIS or SNTI more profitable?

Do analysts rate CRIS or SNTI?

Does the media refer more to CRIS or SNTI?

Summary

How does Curis compare to Soligenix?

Do insiders & institutionals hold more shares of SNGX or CRIS?

Do analysts prefer SNGX or CRIS?

Which has higher earnings and valuation, SNGX or CRIS?

Is SNGX or CRIS more profitable?

Does the media refer more to SNGX or CRIS?

Which has more risk & volatility, SNGX or CRIS?

Summary

How does Curis compare to Imunon?

Is IMNN or CRIS more profitable?

Does the media favor IMNN or CRIS?

Do analysts recommend IMNN or CRIS?

Do insiders and institutionals have more ownership in IMNN or CRIS?

Which has higher valuation & earnings, IMNN or CRIS?

Which has more risk & volatility, IMNN or CRIS?

Summary

How does Curis compare to Cardio Diagnostics?

Which has better valuation and earnings, CRIS or CDIO?

Do institutionals & insiders hold more shares of CRIS or CDIO?

Is CRIS or CDIO more profitable?

Which has more volatility & risk, CRIS or CDIO?

Does the media prefer CRIS or CDIO?

Do analysts recommend CRIS or CDIO?

Summary

How does Curis compare to Xenetic Biosciences?

Which has more volatility and risk, XBIO or CRIS?

Which has preferable valuation and earnings, XBIO or CRIS?

Do institutionals and insiders have more ownership in XBIO or CRIS?

Do analysts recommend XBIO or CRIS?

Is XBIO or CRIS more profitable?

Does the media prefer XBIO or CRIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools